Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of Ovarian carcinomas

PLoS ONE

Volumn 2, Issue 5, 2007, Pages

  Moreno, Carlos S ^a,b   Matyunina, Lilya ^c,d   Dickerson, Erin B ^c,d   Schubert, Nina ^c,d   Bowen, Nathan J ^c,d   Logani, Sanjay ^a   Benigno, Benedict B ^d   McDonald, John F ^c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d Ovarian Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MODEL; GYNECOLOGIC SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATIONAL ANALYSIS; OVARY CARCINOMA; SURVIVAL TIME; TREATMENT OUTCOME; CELL CYCLE; GENETICS; HETEROZYGOSITY LOSS; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THEORETICAL MODEL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; FEMALE; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MODELS, THEORETICAL; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 36549089750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000441     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics. CA Cancer J Clin 56: 106-130.
2. Banks E (2000) The epidemeology of ovarian cancer. In: Bartlett JMS ed. Ovarian Cancer: Methods and Protocols. Totown: Humana Press. pp 3-6.
3. Maloas JS (1979) Chemotherapy in the management of ovarian cancer: a review. J R Soc Med 72: 357-361.
4. Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ (2004) Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer 14: 772-778.
5. Coukos G, Rubin SC (1998) Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstetrics and Gynecology 91: 783-792.
6. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu Y, et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710.
7. Nimeus-Malmstrom E, Ritz C, Eden P, Johnsson A, Ohlsson M, et al. (2006) Gene expression profiles and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer. In press.
8. Ma Y, Yuan RQ, Fan S, Hu C, Goldberg ID, et al. (2006) Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs 17: 733-51.
9. Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, et al. (2001) Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14: 305-315.
10. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, et al. (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911-7918.
11. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
12. Beissbarth T, Speed T (2004) GOstat: Find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 20: 1464-14.
13. Meyer E, Vollmer JY, Bovey R, Stamenkovic I (2005) Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 65: 4261-4272.
14. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, et al. (2003) Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 63: 2782-2793.
15. Sugrue MM, Shin DY, Lee SW, Aaronson SA (1997) Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci U S A 94: 9648-9653.
16. Ameyar M, Shatrov V, Bouquet C, Capoulade C, Cai Z, et al. (1999) Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 18: 5464-5472.
17. Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ (1991) Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A 88: 1958-1962.
18. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, et al. (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. Embo J 19: 6517-6526.
19. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, et al. (2000) Caveolin-1 expression is down-regulated in cells tranformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 39: 13916-13924.
20. Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, et al. (1998) Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene 17: 1089-1096.
21. Liu G, Chen X (2002) The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 21: 7195-7204.
22. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW (2000) DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol 151: 495-506.
23. Yamaguchi A, Taniguchi M, Hori O, Ogawa S, Tojo N, et al. (2002) Peg3/ Pw1 is involved in p53-mediated cell death pathway in brain ischemia/ hypoxia. J Biol Chem 277: 623-629.
24. Tan M, Heizmann GW, Guan K, Schafer BW, Sun Y (1999) Transcriptional activation of the human S100A2 promoter by wild-type p53. FEBS Lett 445: 265-268.
25. Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, et al. (2002) Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 21: 2914-2918.
26. Katabuchi H, Tashiro H, Cho KR, Kurman RJ, Ellenson LH (1998) Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol 17: 54-60.
27. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, et al. (1998) p53 sequence analysis predicts treatment response and outcome of patients with esophageal carrinoma. Cancer 83: 7-18.
28. Feki A, Irminger-Finger I (2004) Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 52: 103-116.
29. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, et al. (1994) The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170: 246-252.
30. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
31. Sionov RV, Haupt Y (1999) The cellular response to p53: the decision between life and death. 18: 6145-6157.
32. Erenpreisa J, Kalejs M, Cragg MS (2005) Mitotic catastrophe and endomitosis in tumor cells: an evolutionary key to a molecular solution. Cell Biol Int 29: 1012-1018.
33. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton NH (2004) Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 57: 503-511.
34. Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cicplatin-induced apoptosis. Head Neck 26: 870-877.
35. Osugi H, Morimura K, Okuda E, Takemura M, Higashino M, Takada N, Kinoshita H (2002) p53 null mutations detected by a p53 yeast functional assay predict a poor outcome in young esophageal carcinoma patients. Int J Oncology 21: 637-641.
36. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP (2000) p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Ped Onc 35: 563-568.
37. Christophorou MA, Ringshausen I, Finch AJ, Brown-Swigart L, Evan GI (2006) The pathological responses to DNA damage does not contribute to p53- mediated tumor suppression. Nature 443: 214-217.
38. Efeyan A, Garcia-Cao I, Herranz D, Velasco-Miguel S, Serrano M (2006) Policing of oncogene activity by p53. Nature 443: 159.
39. Berns A (2006) Can less be more for p53? Nature 443: 153-154.
40. Warenfeltz S, Pavlik S, Datta S, Kraemer ET, Benigno BB, et al. (2004) Gene expression profiling of epithelial ovarian tumors correlated with malignant potential. Mol Can 3: 27-44.
41. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
42. Saldanha AJ (2004) Java Treeview-extensible visualization of microarray data. Biomformatics 20: 3246-3248.
43. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) Gene Pattern 2.0. Nat Genet 38: 500-501.
44. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-DeltaDelta C(T) method. Methods 25: 402-408.
45. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, et al. (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Can Res 7: 2984-2997.